Literature DB >> 12120820

Lower serum digoxin concentrations in heart failure and reassessment of laboratory report forms.

Roya M Sameri1, Judith E Soberman, Christopher K Finch, Timothy H Self.   

Abstract

Serum digoxin concentrations (SDC) have been used clinically since the early 1970s. Whereas the therapeutic range for SDC is frequently cited as either 0.8 to 2.0 ng/mL or 0.5 to 2.0 ng/mL, studies over the past decade suggest an upper limit of 1.0 ng/mL for treating heart failure. The same upper limit for SDC is suggested for patients with heart failure and atrial fibrillation with rapid ventricular response. Reducing the upper limit of the therapeutic range to 1.0 ng/mL on computerized and paper laboratory report forms may guide clinicians to avoid unnecessarily high SDC, thus minimizing risk of digoxin toxicity without sacrificing therapeutic benefit for heart failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12120820     DOI: 10.1097/00000441-200207000-00003

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  2 in total

1.  Therapeutic ranges of serum digoxin concentrations in patients with heart failure.

Authors:  Zachary D Goldberger; Ary L Goldberger
Journal:  Am J Cardiol       Date:  2012-04-11       Impact factor: 2.778

2.  Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.

Authors:  Amitava Dasgupta; Myrtle J Johnson; Tamal K Sengupta
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.